Ubs Asset Management Americas Inc Viridian Therapeutics, Inc.\De Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 115,782 shares of VRDN stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115,782
Previous 89,496
29.37%
Holding current value
$1.97 Million
Previous $2.04 Million
8.99%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VRDN
# of Institutions
203Shares Held
81.6MCall Options Held
502KPut Options Held
870K-
Black Rock Inc. New York, NY4.77MShares$81.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$78.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$77 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$66.1 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$60 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $679M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...